Search

Your search keyword '"Shadman, Mazyar"' showing total 1,075 results
Start Over Author "Shadman, Mazyar"
1,075 results on '"Shadman, Mazyar"'

1. Chimeric antigen receptor T-cell infusion for large B-cell lymphoma in complete remission: a center for international blood and marrow transplant research analysis

Author

Wang, Trent P., Ahn, Kwang W., Shadman, Mazyar, Kaur, Manmeet, Ahmed, Nausheen, Bacher, Ulrike, Cerny, Jan, Chen, Andy, Epperla, Narendranath, Frigault, Matthew, Grover, Natalie, Haverkos, Bradley, Hill, Brian, Hossain, Nasheed, Iqbal, Madiha, Jain, Tania, Krem, Maxwell M., Maakaron, Joseph, Modi, Dipenkumar, Alhaj Moustafa, Muhamad, Riedell, Peter, Savani, Bipin, Sica, R. Alejandro, Sureda, Anna, Wudhikarn, Kitsada, Herrera, Alex F., Sauter, Craig, Hamadani, Mehdi, and Jimenez Jimenez, Antonio

Published
2024
Full Text
View/download PDF

2. Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission

Author

Shadman, Mazyar, Ahn, Kwang W., Kaur, Manmeet, Lekakis, Lazaros, Beitinjaneh, Amer, Iqbal, Madiha, Ahmed, Nausheen, Hill, Brian, Hossain, Nasheed M., Riedell, Peter, Gopal, Ajay K., Grover, Natalie, Frigault, Matthew, Brammer, Jonathan, Ghosh, Nilanjan, Merryman, Reid, Lazaryan, Aleksandr, Ram, Ron, Hertzberg, Mark, Savani, Bipin, Awan, Farrukh, Khimani, Farhad, Ahmed, Sairah, Kenkre, Vaishalee P., Ulrickson, Matthew, Shah, Nirav, Kharfan-Dabaja, Mohamed A., Herrera, Alex, Sauter, Craig, and Hamadani, Mehdi

Published
2024
Full Text
View/download PDF

4. Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial

Author

Hillmen, Peter, Eichhorst, Barbara, Brown, Jennifer R, Lamanna, Nicole, O'Brien, Susan M, Tam, Constantine S, Qiu, Lugui, Kazmierczak, Maciej, Zhou, Keshu, Šimkovič, Martin, Mayer, Jiří, Gillespie-Twardy, Amanda, Shadman, Mazyar, Ferrajoli, Alessandra, Ganly, Peter S, Weinkove, Robert, Grosicki, Sebastian, Mital, Andrzej, Robak, Tadeusz, Österborg, Anders, Yimer, Habte A, Salmi, Tommi, Ji, Meng, Yecies, Jessica, Idoine, Adam, Wu, Kenneth, Huang, Jane, and Jurczak, Wojciech

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Cardiovascular, Hematology, Clinical Research, Lymphoma, Cancer, Rare Diseases, Clinical Trials and Supportive Activities, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Atrial Fibrillation, Adenine, Lymphoma, B-Cell, Protein Kinase Inhibitors, Clinical Sciences, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

PurposeZanubrutinib is a potent, irreversible next-generation Bruton tyrosine kinase (BTK) inhibitor designed to maximize BTK occupancy and minimize off-target kinase inhibition. We hypothesized that complete/sustained BTK occupancy may improve efficacy outcomes and increased BTK specificity may minimize off-target inhibition-related toxicities.Patients and methodsALPINE (ClinicalTrials.gov identifier: NCT03734016) is a global, randomized, open-label phase III study of zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia. The primary end point was investigator-assessed overall response rate (ORR). The preplanned interim analysis was scheduled approximately 12 months after the first 415 patients were enrolled.ResultsBetween November 1, 2018, and December 14, 2020, 652 patients were enrolled. We present the interim analysis of the first 415 enrolled patients randomly assigned to receive zanubrutinib (n = 207) or ibrutinib (n = 208). At 15 months of median follow-up, ORR (partial or complete response) was significantly higher with zanubrutinib (78.3%; 95% CI, 72.0 to 83.7) versus ibrutinib (62.5%; 95% CI, 55.5 to 69.1; two-sided P < .001). ORR was higher with zanubrutinib versus ibrutinib in subgroups with del(17p)/TP53 mutations (80.5% v 50.0%) and del(11q) (83.6% v 69.1%); 12-month progression-free survival in all patients was higher with zanubrutinib (94.9%) versus ibrutinib (84.0%; hazard ratio, 0.40; 95% CI, 0.23 to 0.69). Atrial fibrillation rate was significantly lower with zanubrutinib versus ibrutinib (2.5% v 10.1%; two-sided P = .001). Rates of cardiac events, major hemorrhages, and adverse events leading to treatment discontinuation/death were lower with zanubrutinib.ConclusionZanubrutinib had a significantly higher ORR, lower atrial fibrillation rate, and improved progression-free survival and overall cardiac safety profile versus ibrutinib. These data support improved efficacy/safety outcomes with selective BTK inhibition.

Published
2023

7. Clinical Practice Recommendations for Hematopoietic Cell Transplantation and Cellular Therapies in Follicular Lymphoma: A Collaborative Effort on Behalf of the American Society for Transplantation and Cellular Therapy and the European Society for Blood and Marrow Transplantation

Author

Iqbal, Madiha, Kumar, Ambuj, Dreger, Peter, Chavez, Julio, Sauter, Craig S., Sureda, Anna M., Bachanova, Veronika, Maziarz, Richard T., Dreyling, Martin, Smith, Sonali M., Jacobson, Caron, Glass, Bertram, Casulo, Carla, Oluwole, Olalekan O., Montoto, Silvia, Advani, Ranjana, Cohen, Jonathon, Salles, Gilles, Hamad, Nada, Kuruvilla, John, Kahl, Brad S., Shadman, Mazyar, Kanate, Abraham S., Budde, Lihua Elizabeth, Kamdar, Manali, Flowers, Christopher, Hamadani, Mehdi, and Kharfan-Dabaja, Mohamed A.

Published
2024
Full Text
View/download PDF

8. Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity

Author

Locke, Frederick L., Siddiqi, Tanya, Jacobson, Caron A., Ghobadi, Armin, Ahmed, Sairah, Miklos, David B., Perales, Miguel-Angel, Munoz, Javier, Fingrut, Warren B., Pennisi, Martina, Gauthier, Jordan, Shadman, Mazyar, Gowda, Lohith, Mirza, Abu-Sayeef, Abid, Muhammad Bilal, Hong, Sanghee, Majhail, Navneet S., Kharfan-Dabaja, Mohamed A., Khurana, Arushi, Badar, Talha, Lin, Yi, Bennani, N. Nora, Herr, Megan M., Hu, Zhen-Huan, Wang, Hai-Lin, Baer, Anjani, Baro, Elande, Miao, Harry, Spooner, Clare, Xu, Hairong, and Pasquini, Marcelo C.

Published
2024
Full Text
View/download PDF

9. Hypertension treatment for patients receiving ibrutinib: a multicenter retrospective study

Author

Samples, Laura, Voutsinas, Jenna, Fakhri, Bita, Khajavian, Sirin, Spurgeon, Stephen, Stephens, Deborah, Skarbnik, Alan, Mato, Anthony, Broome, Catherine, Gopal, Ajay, Smith, Stephen, Lynch, Ryan, Rainey, Magdalena, Kim, Myung Sun, Barrett-Campbell, Odeth, Hemond, Emily, Tsang, Mazie, Ermann, Daniel, Malakhov, Nikita, Rao, Danielle, Shakib-Azar, Mehrdad, Morrigan, Beth, Chauhan, Ayushi, Plate, Thomas, Gooley, Ted, Ryan, Kellie, Lansigan, Frederick, Hill, Brian, Pongas, Georgios, Parikh, Sameer A., Roeker, Lindsey, Allan, John N., Cheng, Richard, Ujjani, Chaitra, and Shadman, Mazyar

Published
2024
Full Text
View/download PDF

10. Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: “What's Past Is Prologue” (Shakespeare)CLL/SLL Unmet Need

Author

Mato, Anthony R, Davids, Matthew S, Sharman, Jeff, Roeker, Lindsey E, Kay, Neil, Kater, Arnon P, Rogers, Kerry, Thompson, Meghan C, Rhodes, Joanna, Goy, Andre, Skarbnik, Alan, Schuster, Stephen J, Tam, Constantine S, Eyre, Toby A, O'Brien, Susan, Nabhan, Chadi, Lamanna, Nicole, Sun, Clare, Shadman, Mazyar, Pagel, John M, Ujjani, Chaitra, Brander, Danielle, Coombs, Catherine C, Jain, Nitin, Cheah, Chan Y, Brown, Jennifer R, Seymour, John F, and Woyach, Jennifer A

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Rare Diseases, Clinical Research, Hematology, Lymphoma, Cancer, Humans, Immunotherapy, Leukemia, Lymphocytic, Chronic, B-Cell, Phosphatidylinositol 3-Kinases, Protein Kinase Inhibitors, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
Abstract

The management of chronic lymphocytic leukemia (CLL) has undergone unprecedented changes over the last decade. Modern targeted therapies are incorporated into clinical practice. Unfortunately, patients have begun to develop resistance or intolerance to multiple classes. Symptomatic patients previously treated with a BTK inhibitor (BTKi) and venetoclax represent a new and rapidly growing unmet need in CLL. Here, we define unmet needs in a modern treatment context. We also critically review the literature for PI3K inhibitors and chemoimmunotherapy and lack of data to support their utility following BTKis and venetoclax. Finally, we suggest opportunities to ensure the continued innovation for patients with CLL.

Published
2022

12. The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model.

Author

Gordon, Max, Kaempf, Andy, Sitlinger, Andrea, Shouse, Geoffrey, Mei, Matthew, Brander, Danielle, Salous, Tareq, Hill, Brian, Alqahtani, Hamood, Choi, Michael, Churnetski, Michael, Cohen, Jonathon, Stephens, Deborah, Siddiqi, Tanya, Rivera, Xavier, Persky, Daniel, Wisniewski, Paul, Patel, Krish, Shadman, Mazyar, Park, Byung, and Danilov, Alexey

Subjects
Adult, Aged, Aged, 80 and over, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Middle Aged, Progression-Free Survival, Proportional Hazards Models, Retrospective Studies
Abstract

PURPOSE: Comorbid medical conditions define a subset of patients with chronic lymphocytic leukemia (CLL) with poor outcomes. However, which comorbidities are most predictive remains understudied. EXPERIMENTAL DESIGN: We conducted a retrospective analysis from 10 academic centers to ascertain the relative importance of comorbidities assessed by the cumulative illness rating scale (CIRS). The influence of specific comorbidities on event-free survival (EFS) was assessed in this derivation dataset using random survival forests to construct a CLL-specific comorbidity index (CLL-CI). Cox models were then fit to this dataset and to a single-center, independent validation dataset. RESULTS: The derivation and validation sets comprised 570 patients (59% receiving Bruton tyrosine kinase inhibitor, BTKi) and 167 patients (50% receiving BTKi), respectively. Of the 14 CIRS organ systems, three had a strong and stable influence on EFS: any vascular, moderate/severe endocrine, moderate/severe upper gastrointestinal comorbidity. These were combined to create the CLL-CI score, which was categorized into 3 risk groups. In the derivation dataset, the median EFS values were 58, 33, and 20 months in the low, intermediate, and high-risk groups, correspondingly. Two-year overall survival (OS) rates were 96%, 91%, and 82%. In the validation dataset, median EFS values were 81, 40, and 23 months (two-year OS rates 97%/92%/88%), correspondingly. Adjusting for prognostic factors, CLL-CI was significantly associated with EFS in patients treated with either chemo-immunotherapy or with BTKi in each of our 2 datasets. CONCLUSIONS: The CLL-CI is a simplified, CLL-specific comorbidity index that can be easily applied in clinical practice and correlates with survival in CLL.

Published
2021

13. Timing of anti–PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma

Author

Hirayama, Alexandre V., Kimble, Erik L., Wright, Jocelyn H., Fiorenza, Salvatore, Gauthier, Jordan, Voutsinas, Jenna M., Wu, Qian, Yeung, Cecilia C. S., Gazeau, Nicolas, Pender, Barbara S., Kirchmeier, Delaney R., Torkelson, Aiko, Chutnik, Abigail N., Cassaday, Ryan D., Chapuis, Aude G., Green, Damian J., Kiem, Hans-Peter, Milano, Filippo, Shadman, Mazyar, Till, Brian G., Riddell, Stanley R., Maloney, David G., and Turtle, Cameron J.

Published
2024
Full Text
View/download PDF

14. Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINE

Author

Brown, Jennifer R., Eichhorst, Barbara, Lamanna, Nicole, O’Brien, Susan M., Tam, Constantine S., Qiu, Lugui, Jurczak, Wojciech, Zhou, Keshu, Simkovic, Martin, Mayer, Jiri, Gillespie-Twardy, Amanda, Ferrajoli, Alessandra, Ganly, Peter S., Weinkove, Robert, Grosicki, Sebastian, Mital, Andrzej, Robak, Tadeusz, Osterborg, Anders, Yimer, Habte A., Wang, Megan (Der Yu), Salmi, Tommi, Wang, Liping, Li, Jessica, Wu, Kenneth, Cohen, Aileen, and Shadman, Mazyar

Published
2024
Full Text
View/download PDF

17. Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma

Author

Bartlett, Nancy L., Assouline, Sarit, Giri, Pratyush, Schuster, Stephen J., Cheah, Chan Y., Matasar, Matthew, Gregory, Gareth P., Yoon, Dok Hyun, Shadman, Mazyar, Fay, Keith, Yoon, Sung-Soo, Panizo, Carlos, Flinn, Ian, Johnston, Anna, Bosch, Francesc, Sehn, Laurie H., Wei, Michael C., Yin, Shen, To, Iris, Li, Chi-Chung, Huang, Huang, Kwan, Antonia, Penuel, Elicia, and Budde, Lihua E.

Published
2023
Full Text
View/download PDF

18. Diminished humoral and cellular responses to SARS-CoV-2 vaccines in patients with chronic lymphocytic leukemia

Author

Ujjani, Chaitra, Gooley, Ted A., Spurgeon, Stephen E., Stephens, Deborah M., Lai, Catherine, Broome, Catherine M., O’Brien, Susan, Zhu, Haiying, Laing, Kerry J., Winter, Allison M., Pongas, Georgios, Greninger, Alexander L, Koelle, David M., Siddiqi, Tanya, Davids, Matthew S., Rogers, Kerry A., Danilov, Alexey V., Sperling, Amy, Tu, Brian, Sorensen, Tyler, Launchbury, Kelsey, Burrow, Carlissa J., Quezada, Genesis, Hill, Joshua A., Shadman, Mazyar, and Thompson, Philip A.

Published
2023
Full Text
View/download PDF

19. A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma

Author

Shouse, Geoffrey, Kaempf, Andy, Gordon, Max J., Artz, Andy, Yashar, David, Sigmund, Audrey M., Smilnak, Gordon, Bair, Steven M., Mian, Agrima, Fitzgerald, Lindsey A., Bajwa, Amneet, Jaglowski, Samantha, Bailey, Neil, Shadman, Mazyar, Patel, Krish, Stephens, Deborah M., Kamdar, Manali, Hill, Brian T., Gauthier, Jordan, Karmali, Reem, Nastoupil, Loretta J., Kittai, Adam S., and Danilov, Alexey V.

Published
2023
Full Text
View/download PDF

20. Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy

Author

Gazeau, Nicolas, Liang, Emily C., Wu, Qian “Vicky”, Voutsinas, Jenna M., Barba, Pere, Iacoboni, Gloria, Kwon, Mi, Ortega, Juan Luis Reguera, López-Corral, Lucía, Hernani, Rafael, Ortiz-Maldonado, Valentín, Martínez-Cibrian, Nuria, Martinez, Antonio Perez, Maziarz, Richard T., Williamson, Staci, Nemecek, Eneida R., Shadman, Mazyar, Cowan, Andrew J., Green, Damian J., Kimble, Erik, Hirayama, Alexandre V., Maloney, David G., Turtle, Cameron J., and Gauthier, Jordan

Published
2023
Full Text
View/download PDF

21. Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study

Author

Shadman, Mazyar, Manzoor, Beenish S., Sail, Kavita, Tuncer, Hande H., Allan, John N., Ujjani, Chaitra, Emechebe, Nnadozie, Kamalakar, Rajesh, Coombs, Catherine C., Leslie, Lori, Barr, Paul M., Brown, Jennifer R., Eyre, Toby A., Rampotas, Alexandros, Schuh, Anna, Lamanna, Nicole, Skarbnik, Alan, Roeker, Lindsey E., Bannerji, Rajat, Eichhorst, Barbara, Fleury, Isabelle, Davids, Matthew S., Alhasani, Hasan, Jiang, Dingfeng, Hill, Brian T., Schuster, Stephen J., Brander, Danielle M., Pivneva, Irina, Burne, Rebecca, Guerin, Annie, and Mato, Anthony R.

Published
2023
Full Text
View/download PDF

22. γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial

Author

Cowan, Andrew J, Pont, Margot J, Sather, Blythe D, Turtle, Cameron J, Till, Brian G, Libby, Edward N, 3rd, Coffey, David G, Tuazon, Sherilyn A, Wood, Brent, Gooley, Ted, Wu, Vicky Q, Voutsinas, Jenna, Song, Xiaoling, Shadman, Mazyar, Gauthier, Jordan, Chapuis, Aude G, Milano, Filippo, Maloney, David G, Riddell, Stanley R, and Green, Damian J

Published
2023
Full Text
View/download PDF

23. Polatuzumab vedotin with infusional chemotherapy for untreated aggressive B-cell non-Hodgkin lymphomas

Author

Lynch, Ryan C., Poh, Christina, Ujjani, Chaitra S., Warren, Edus H., III, Smith, Stephen D., Shadman, Mazyar, Morris, Karolyn, Lee, Sydney, Rasmussen, Heather, Ottemiller, Susan, Shelby, Megan, Keo, Sarith, Verni, Kaitlin, Kurtz, David M., Alizadeh, Ash A., Chabon, Jacob J., Hogan, Gregory J., Schulz, Andre, Gooley, Ted, Voutsinas, Jenna M., and Gopal, Ajay K.

Published
2023
Full Text
View/download PDF

24. Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma

Author

Lynch, Ryan C., Ujjani, Chaitra S., Poh, Christina, Warren, Edus H., Smith, Stephen D., Shadman, Mazyar, Till, Brian, Raghunathan, Vikram M., Alig, Stefan, Alizadeh, Ash A., Gulhane, Avanti, Chen, Delphine L., Tseng, Yolanda, Coye, Hilary, Shelby, Megan, Ottemiller, Susan, Keo, Sarith, Verni, Kaitlin, Du, Hongyan, Vandermeer, Jacquelin, Gaston, Ashley, Rasmussen, Heather, Martin, Paul, Marzbani, Edmond, Voutsinas, Jenna, and Gopal, Ajay K.

Published
2023
Full Text
View/download PDF

25. Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy.

Author

Mato, Anthony R, Roeker, Lindsey E, Jacobs, Ryan, Hill, Brian T, Lamanna, Nicole, Brander, Danielle, Shadman, Mazyar, Ujjani, Chaitra S, Yazdy, Maryam Sarraf, Perini, Guilherme Fleury, Pinilla-Ibarz, Javier A, Barrientos, Jacqueline, Skarbnik, Alan P, Torka, Pallawi, Pu, Jeffrey J, Pagel, John M, Gohil, Satyen, Fakhri, Bita, Choi, Michael, Coombs, Catherine C, Rhodes, Joanna, Barr, Paul M, Portell, Craig A, Parry, Helen, Garcia, Christine A, Whitaker, Kate J, Winter, Allison M, Sitlinger, Andrea, Khajavian, Sirin, Grajales-Cruz, Ariel F, Isaac, Krista M, Shah, Pratik, Akhtar, Othman S, Pocock, Rachael, Lam, Kentson, Voorhees, Timothy J, Schuster, Stephen J, Rodgers, Thomas D, Fox, Christopher P, Martinez-Calle, Nicolas, Munir, Talha, Bhavsar, Erica B, Bailey, Neil, Lee, Jason C, Weissbrot, Hanna B, Nabhan, Chadi, Goodfriend, Julie M, King, Amber C, Zelenetz, Andrew D, Dorsey, Colleen, Bigelow, Kayla, Cheson, Bruce D, Allan, John N, and Eyre, Toby A

Subjects
Humans, Sulfonamides, Pyrazoles, Pyrimidines, Protein Kinase Inhibitors, Leukemia, Lymphocytic, Chronic, B-Cell, Phosphatidylinositol 3-Kinases, Bridged Bicyclo Compounds, Heterocyclic, Rare Diseases, Cancer, Clinical Research, Hematology, Good Health and Well Being, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeVenetoclax-based therapy is a standard-of-care option in first-line and relapsed/refractory chronic lymphocytic leukemia (CLL). Patient management following venetoclax discontinuation remains nonstandard and poorly understood.Experimental designTo address this, we conducted a large international study to identify a cohort of 326 patients who discontinued venetoclax and have been subsequently treated. Coprimary endpoints were overall response rate (ORR) and progression-free survival for the post-venetoclax treatments stratified by treatment type [Bruton's tyrosine kinase inhibitor (BTKi), PI3K inhibitor (PI3Ki), and cellular therapies].ResultsWe identified patients with CLL who discontinued venetoclax in the first-line (4%) and relapsed/refractory settings (96%). Patients received a median of three therapies prior to venetoclax; 40% were BTKi naïve (n = 130), and 81% were idelalisib naïve (n = 263). ORR to BTKi was 84% (n = 44) in BTKi-naïve patients versus 54% (n = 30) in BTKi-exposed patients. We demonstrate therapy selection following venetoclax requires prior novel agent exposure consideration and discontinuation reasons.ConclusionsFor BTKi-naïve patients, selection of covalently binding BTKis results in high ORR and durable remissions. For BTKi-exposed patients, covalent BTK inhibition is not effective in the setting of BTKi resistance. PI3Kis following venetoclax do not appear to result in durable remissions. We conclude that BTKi in naïve or previously responsive patients and cellular therapies following venetoclax may be the most effective strategies.See related commentary by Rogers, p. 3501.

Published
2020

26. The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia.

Author

Eyre, Toby, Roeker, Lindsey, Fox, Christopher, Gohill, Satyen, Walewska, Renata, Walter, Harriet, Forconi, Francesco, Broom, Angus, Arumainathan, Arvind, Brander, Danielle, Allan, John, Schuster, Stephen, Hill, Brian, Lansigan, Frederick, Cheson, Bruce, Lamanna, Nicole, Coombs, Catherine, Barr, Paul, Skarbnik, Alan, Shadman, Mazyar, Ujjani, Chaitra, Pearson, Laurie, Pagel, John, Jacobs, Ryan, and Mato, Anthony

Subjects
BCL2, chronic lymphocytic leukaemia, elderly, venetoclax, Aged, Antineoplastic Agents, Bridged Bicyclo Compounds, Heterocyclic, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Recurrence, Sulfonamides
Abstract

Elderly chronic lymphocytic leukaemia (CLL) patients treated outside of trials have notably greater toxicity with the Brutons tyrosine kinase inhibitor ibrutinib compared to younger patients. It is not known whether the same holds true for the B-cell lymphoma 2 inhibitor venetoclax. We provide a comprehensive analysis of key safety measures and efficacy in 342 patients comparing age categories ≥75 and

Published
2020

28. Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study

Author

Shadman, Mazyar, Flinn, Ian W, Levy, Moshe Y, Porter, Ryan F, Burke, John M, Zafar, Syed F, Misleh, Jamal, Kingsley, Edwin C, Yimer, Habte A, Freeman, Benjamin, Rao, Subramanya S, Chaudhry, Arvind, Tumula, Praveen K, Gandhi, Mitul D, Manda, Sudhir, Chen, Dih-Yih, By, Kunthel, Xu, Linlin, Liu, Ye, Crescenzo, Rocco, Idoine, Adam, Zhang, Xiaoping, Cohen, Aileen, Huang, Jane, and Sharman, Jeff P

Published
2023
Full Text
View/download PDF

29. Comparative efficacy of Bruton tyrosine kinase inhibitors in the treatment of relapsed/refractory chronic lymphocytic leukemia: A network meta-analysis (NMA).

Author

Shadman, Mazyar, primary, Brown, Jennifer R., additional, Mohseninejad, Leyla, additional, Yang, Keri, additional, Burnett, Heather, additional, Neupane, Binod, additional, Williams, Rhys, additional, Lamanna, Nicole, additional, O'Brien, Susan M., additional, Tedeschi, Alessandra, additional, and Tam, Constantine S., additional

Published
2024
Full Text
View/download PDF

30. Early prediction of severe ICANS after standard-of-care CD19 CAR T-cell therapy using gradient-boosted classification trees.

Author

Huang, Jennifer Jing, primary, Liang, Emily C., additional, Albittar, Aya, additional, Portuguese, Andrew Jay, additional, Wuliji, Natalie, additional, Torkelson, Aiko, additional, Kirchmeier, Delaney, additional, Chutnik, Abigail, additional, Pender, Barbara, additional, Shadman, Mazyar, additional, Hirayama, Alexandre V., additional, Till, Brian G., additional, Kimble, Erik Lesley, additional, Iovino, Lorenzo, additional, Chapuis, Aude, additional, Otegbeye, Folashade, additional, Cassaday, Ryan Daniel, additional, Milano, Filippo, additional, Maloney, David G., additional, and Gauthier, Jordan, additional

Published
2024
Full Text
View/download PDF

31. Predictors of severe hematotoxicity after CAR T-cell therapy.

Author

Liang, Emily C., primary, Albittar, Aya, additional, Portuguese, Andrew Jay, additional, Huang, Jennifer Jing, additional, Torkelson, Aiko, additional, Kirchmeier, Delaney, additional, Chutnik, Abigail, additional, Pender, Barbara, additional, Hill, Joshua A., additional, Kopmar, Noam Edward, additional, Banerjee, Rahul, additional, Cowan, Andrew, additional, Poh, Christina, additional, Shadman, Mazyar, additional, Hirayama, Alexandre V., additional, Till, Brian G., additional, Kimble, Erik Lesley, additional, Iovino, Lorenzo, additional, Cassaday, Ryan Daniel, additional, and Gauthier, Jordan, additional

Published
2024
Full Text
View/download PDF

32. Real-world outcomes following adverse events and dose reduction of first-line ibrutinib in Medicare beneficiaries with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

Author

Shadman, Mazyar, primary, Srivastava, Bhavini P., additional, Salkar, Monika, additional, Saifan, Chadi, additional, Agatep, Barnabie C., additional, Jones, Barton, additional, Ryan, Olga, additional, Bacchus, Shaffee, additional, and Stephens, Deborah M., additional

Published
2024
Full Text
View/download PDF

33. Chimeric antigen receptor T‐cell therapy in secondary central nervous system lymphoma: A multicenter analysis

Author

Alsouqi, Aseel, primary, Ahmed, Gulrayz, additional, Wang, Juntian, additional, Cassanello, Guilio, additional, Szabo, Aniko, additional, Rojek, Alexandra E., additional, Riedell, Peter A., additional, Awan, Farrukh, additional, Samples, Laura, additional, Shadman, Mazyar, additional, Hu, Marie, additional, Bachanova, Veronika, additional, Wesson, William, additional, Ahmed, Nausheen, additional, Iqbal, Madiha, additional, Kharfan‐Dabaja, Mohamed A., additional, Scordo, Michael, additional, Johnson, P. Connor, additional, Chen, Yi‐Bin, additional, Ito, Sawa, additional, Hamadani, Mehdi, additional, and Frigault, Matthew, additional

Published
2024
Full Text
View/download PDF

34. Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice.

Author

Roeker, Lindsey, Fox, Christopher, Eyre, Toby, Brander, Danielle, Allan, John, Schuster, Stephen, Nabhan, Chadi, Hill, Brian, Shah, Nirav, Lansigan, Frederick, Yazdy, Maryam, Cheson, Bruce, Lamanna, Nicole, Singavi, Arun, Coombs, Catherine, Barr, Paul, Skarbnik, Alan, Shadman, Mazyar, Ujjani, Chaitra, Tuncer, Hande, Winter, Allison, Rhodes, Joanna, Dorsey, Colleen, Morse, Hannah, Kabel, Charlene, Pagel, John, Williams, Annalynn, Jacobs, Ryan, Goy, Andre, Muralikrishnan, Sivraj, Pearson, Laurie, Sitlinger, Andrea, Bailey, Neil, Schuh, Anna, Kirkwood, Amy, and Mato, Anthony

Subjects
Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Bridged Bicyclo Compounds, Heterocyclic, Dose-Response Relationship, Drug, Drug-Related Side Effects and Adverse Reactions, Female, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Male, Middle Aged, Patient Safety, Practice Patterns, Physicians, Proto-Oncogene Proteins c-bcl-2, Retrospective Studies, Sulfonamides, Treatment Outcome, Tumor Lysis Syndrome
Abstract

PURPOSE: Clinical trials of venetoclax reported negligible rates of clinical tumor lysis syndrome (TLS) in patients with chronic lymphocytic leukemia (CLL) when using an extended dose escalation schedule. We aimed to understand TLS prophylaxis, rates of select adverse events (AE), and impact of dosing modifications in routine clinical practice. EXPERIMENTAL DESIGN: This retrospective cohort study included 297 CLL venetoclax-treated patients outside of clinical trials in academic and community centers. Demographics, baseline disease characteristics, venetoclax dosing, TLS risk and prophylaxis, and AEs were collected. RESULTS: The group was 69% male, 96% had relapsed/refractory CLL, 45% had deletion chromosome 17p, 84% had unmutated IGHV, 80% received venetoclax monotherapy, and median age was 67. TLS risk was categorized as low (40%), intermediate (32%), or high (28%), and 62% had imaging prior to venetoclax initiation. Clinical TLS occurred in 2.7% of patients and laboratory TLS occurred in 5.7%. Pre-venetoclax TLS risk group and creatinine clearance independently predict TLS development in multivariable analysis. Grade 3/4 AEs included neutropenia (39.6%), thrombocytopenia (29.2%), infection (25%), neutropenic fever (7.9%), and diarrhea (6.9%). Twenty-two patients (7.4%) discontinued venetoclax due to an AE. Progression-free survival was similar regardless of number of dose interruptions, length of dose interruption, and stable venetoclax dose. CONCLUSIONS: These data provide insights into current use of venetoclax in clinical practice, including TLS rates observed in clinical practice. We identified opportunities for improved adherence to TLS risk stratification and prophylaxis, which may improve safety.

Published
2019

35. A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL.

Author

Mato, Anthony, Roeker, Lindsey, Eyre, Toby, Nabhan, Chadi, Lamanna, Nicole, Hill, Brian, Brander, Danielle, Barr, Paul, Lansigan, Frederick, Cheson, Bruce, Singavi, Arun, Yazdy, Maryam, Shah, Nirav, Allan, John, Bhavsar, Erica, Rhodes, Joanna, Kennard, Kaitlin, Schuster, Stephen, Williams, AnnaLynn, Skarbnik, Alan, Goy, Andre, Goodfriend, Julie, Dorsey, Colleen, Coombs, Catherine, Tuncer, Hande, Ujjani, Chaitra, Jacobs, Ryan, Winter, Allison, Pagel, John, Bailey, Neil, Schuh, Anna, Shadman, Mazyar, Sitlinger, Andrea, Weissbrot, Hanna, Muralikrishnan, Sivraj, Zelenetz, Andrew, Kirkwood, Amy, and Fox, Christopher

Subjects
Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Bridged Bicyclo Compounds, Heterocyclic, Female, Humans, Leukemia, Lymphocytic, Chronic, B-Cell, Male, Middle Aged, Progression-Free Survival, Retrospective Studies, Sulfonamides
Abstract

Venetoclax (VEN) is approved for relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) as monotherapy (VENmono) or in combination with rituximab. Whether VEN plus anti-CD20 (VENcombo) is superior to VENmono is unknown. We conducted a multicenter, retrospective cohort analysis comparing 321 CLL patients treated with VENmono vs VENcombo across the United States and the United Kingdom. We examined demographics, baseline characteristics, dosing, adverse events, response rates, and outcomes. The primary endpoints were progression-free survival (PFS) and overall survival (OS), estimated by Kaplan-Meier method, in patients treated with VENmono vs VENcombo. Univariate and bivariate analyses were performed with COX regression. Three hundred twenty-one CLL patients were included (3 median prior treatments, 78% prior ibrutinib). The overall response rates (ORRs) were similar (VENmono, 81% ORR, 34% complete remission [CR] vs VENcombo, 84% ORR, 32% CR). With a median follow-up of 13.4 months, no differences in PFS and OS were observed between the groups. In unadjusted analyses, the hazard ratios (HRs) for PFS and OS for VENmono vs VENcombo were HR 1.0 (95% confidence interval [CI], 0.6-1.8; P = .7) and HR 1.2 (95% CI, 0.6-2.3; P = .5), respectively. When adjusting for differences between the cohorts, the addition of an anti-CD20 antibody in combination with VEN did not impact PFS (HR, 1.0; 95% CI, 0.5-2.0; P = .9) or OS (HR, 1.1; 95% CI, 0.4-2.6; P = .8). We demonstrate comparable efficacy between VENmono and VENcombo in a heavily pretreated, high-risk, retrospective cohort, in terms of both response data and survival outcomes. Prospective studies are needed to validate these findings.

Published
2019

36. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial

Author

Tam, Constantine S, Brown, Jennifer R, Kahl, Brad S, Ghia, Paolo, Giannopoulos, Krzysztof, Jurczak, Wojciech, Šimkovič, Martin, Shadman, Mazyar, Österborg, Anders, Laurenti, Luca, Walker, Patricia, Opat, Stephen, Chan, Henry, Ciepluch, Hanna, Greil, Richard, Tani, Monica, Trněný, Marek, Brander, Danielle M, Flinn, Ian W, Grosicki, Sebastian, Verner, Emma, Tedeschi, Alessandra, Li, Jianyong, Tian, Tian, Zhou, Lei, Marimpietri, Carol, Paik, Jason C, Cohen, Aileen, Huang, Jane, Robak, Tadeusz, and Hillmen, Peter

Published
2022
Full Text
View/download PDF

37. Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL

Author

Gauthier, Jordan, Gazeau, Nicolas, Hirayama, Alexandre V., Hill, Joshua A., Wu, Vicky, Cearley, Aisling, Perkins, Paula, Kirk, Angela, Shadman, Mazyar, Chow, Victor A., Gopal, Ajay K., Hodges Dwinal, Alexandria, Williamson, Staci, Myers, Jessie, Chen, Andy, Nagle, Sarah, Hayes-Lattin, Brandon, Schachter, Levanto, Maloney, David G., Turtle, Cameron J., Sorror, Mohamed L., and Maziarz, Richard T.

Published
2022
Full Text
View/download PDF

38. Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission

Author

Shadman, Mazyar, Pasquini, Marcelo, Ahn, Kwang Woo, Chen, Yue, Turtle, Cameron J., Hematti, Peiman, Cohen, Jonathon B., Khimani, Farhad, Ganguly, Siddhartha, Merryman, Reid W., Yared, Jean A., Locke, Frederick L., Ahmed, Nausheen, Munshi, Pashna N., Beitinjaneh, Amer, Reagan, Patrick M., Herrera, Alex F., Sauter, Craig S., Kharfan-Dabaja, Mohamed A., and Hamadani, Mehdi

Published
2022
Full Text
View/download PDF

39. Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics

Author

Hamadani, Mehdi, Ngoya, Maud, Sureda, Anna, Bashir, Qaiser, Litovich, Carlos Alejandro, Finel, Hervé, Chen, Yue, Boumendil, Ariane, Zain, Jasmine, Castagna, Luca, Cashen, Amanda F., Blaise, Didier, Shadman, Mazyar, Pastano, Rocco, Khimani, Farhad, Arat, Mutlu, Dietrich, Sascha, Schmitz, Norbert, Glass, Bertram, Kharfan-Dabaja, Mohamed A., Corradini, Paolo, Sauter, Craig S., Montoto, Silvia, Kwon, Mi, Herrera, Alex F., and Dreger, Peter

Published
2022
Full Text
View/download PDF

41. Real-world outcomes following ibrutinib dose reduction in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

Author

Shadman, Mazyar, Salkar, Monika, Srivastava, Bhavini, Karve, Sudeep, Emond, Bruno, Gogna, Priyanka, Manceur, Ameur M., Lafeuille, Marie-Hélène, Rava, Andrew, Sun, Haiyan, Howarth, Amanda, Tomicki, Samantha, Agatep, Barnabie, Jones, Barton, Franceschini, Erin, Saifan, Chadi, Bacchus, Shaffee, Roeker, Lindsey, and Stephens, Deborah M.

Subjects
*CHRONIC lymphocytic leukemia, *MEDICAL care costs, *CARDIAC patients, *DATABASES, *LYMPHOMAS
Abstract

AbstractThis study used real-world data from three separate United States (US) databases to evaluate dosing patterns and time to next treatment (TTNT) following the first-incident adverse event (AE) in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) treated with first-line ibrutinib with and without dose reduction (DR). Median TTNT or death in patients with and without a DR following an AE in each database was as follows: Optum Clinformatics Data Mart (CDM): 59.5 and 30.6 months; ConcertAI: 27.1 and 18.0 months; and Medicare Fee-for-Service (FFS): 49.8 and 22.0 months, respectively. Median TTNT or death in patients with cardiac AEs, with and without a DR, was: Optum CDM: 44.4 and 22.9 months; ConcertAI: 29.9 and 18.3 months; and Medicare FFS: 49.6 and 14.0 months, respectively. Ibrutinib DR was associated with fewer outpatient visits and lower CLL/SLL-related medical costs. These findings suggest that utilizing ibrutinib DR may effectively manage tolerability without compromising clinical efficacy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

43. ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma

Author

Munshi, Pashna N., Hamadani, Mehdi, Kumar, Ambuj, Dreger, Peter, Friedberg, Jonathan W., Dreyling, Martin, Kahl, Brad, Jerkeman, Mats, Kharfan-Dabaja, Mohamed A., Locke, Frederick L., Shadman, Mazyar, Hill, Brian T., Ahmed, Sairah, Herrera, Alex F., Sauter, Craig S., Bachanova, Veronika, Ghosh, Nilanjan, Lunning, Matthew, Kenkre, Vaishalee P., Aljurf, Mahmoud, Wang, Michael, Maddocks, Kami J., Leonard, John P., Kamdar, Manali, Phillips, Tycel, Cashen, Amanda F., Inwards, David J., Sureda, Anna, Cohen, Jonathon B., Smith, Sonali M., Carlo-Stella, Carmello, Savani, Bipin, Robinson, Stephen P., and Fenske, Timothy S.

Published
2021
Full Text
View/download PDF

44. Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study

Author

Kittai, Adam S., primary, Bond, David, additional, Huang, Ying, additional, Bhat, Seema A., additional, Blyth, Emily, additional, Byrd, John C., additional, Chavez, Julio C., additional, Davids, Matthew S., additional, Dela Cruz, Jamie P., additional, Dowling, Mark R., additional, Duffy, Caitlyn, additional, Ho, Carrie, additional, Jacobson, Caron, additional, Jaglowski, Samantha, additional, Jain, Nitin, additional, Lin, Kevin H., additional, Miller, Cecelia, additional, McCarthy, Christine, additional, Omer, Zulfa, additional, Parry, Erin, additional, Rai, Manoj, additional, Rogers, Kerry A., additional, Saha, Aditi, additional, Schachter, Levanto, additional, Scott, Hamish, additional, Senapati, Jayastu, additional, Shadman, Mazyar, additional, Siddiqi, Tanya, additional, Stephens, Deborah M., additional, Vanguru, Vinay, additional, Wierda, William, additional, Woyach, Jennifer A., additional, and Thompson, Philip A., additional

Published
2024
Full Text
View/download PDF

45. Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study

Author

Budde, Lihua E., primary, Assouline, Sarit, additional, Sehn, Laurie H., additional, Schuster, Stephen J., additional, Yoon, Sung-Soo, additional, Yoon, Dok Hyun, additional, Matasar, Matthew J., additional, Bosch, Francesc, additional, Kim, Won Seog, additional, Nastoupil, Loretta J., additional, Flinn, Ian W., additional, Shadman, Mazyar, additional, Diefenbach, Catherine, additional, Cheah, Chan Yoon, additional, Ma, Connie Y., additional, Huang, Huang, additional, Kwan, Antonia, additional, Wei, Michael C., additional, Yin, Shen, additional, and Bartlett, Nancy L., additional

Published
2024
Full Text
View/download PDF

46. Characterization of zanubrutinib safety and tolerability profile and comparison with ibrutinib safety profile in patients with B-cell malignancies: post hoc analysis of a large clinical trial safety database

Author

Brown, Jennifer R., primary, Ghia, Paolo, additional, Jurczak, Wojciech, additional, Kahl, Brad S., additional, Lamanna, Nicole, additional, Robak, Tadeusz, additional, Shadman, Mazyar, additional, Tam, Constantine S., additional, Qiu, Lugui, additional, Paik, Jason, additional, Salmi, Tommi, additional, Wang, Liping, additional, Zhang, Jun, additional, Zhang, Meng, additional, Cohen, Aileen, additional, Ma, Han, additional, and Tedeschi, Alessandra, additional

Published
2024
Full Text
View/download PDF

47. Hypertension Treatment in Patients Receiving Ibrutinib: A Multicenter Retrospective Study

Author

Samples, Laura, primary, Voutsinas, Jenna M., additional, Fakhri, Bita, additional, Khajavian, Sirin, additional, Spurgeon, Stephen E., additional, Stephens, Deborah M., additional, Skarbnik, Alan P, additional, Mato, Anthony R, additional, Broome, Catherine, additional, Gopal, Ajay K., additional, Smith, Stephen D, additional, Lynch, Ryan C, additional, Rainey, Magdalena A, additional, Kim, Myung Sun, additional, Barrett-Campbell, Odeth, additional, Hemond, Emily, additional, Tsang, Mazie, additional, Ermann, Daniel A., additional, Malakhov, Nikita, additional, Rao, Danielle, additional, Shakib-Azar, Mehrdad, additional, Morrigan, Beth, additional, Chauhan, Ayushi, additional, Plate, Thomas, additional, Gooley, Ted A., additional, Ryan, Kellie, additional, Lansigan, Frederick, additional, Hill, Brian T., additional, Pongas, Georgios, additional, Parikh, Sameer A, additional, Roeker, Lindsey Elizabeth, additional, Allan, John N, additional, Cheng, Richard, additional, Ujjani, Chaitra, additional, and Shadman, Mazyar, additional

Published
2024
Full Text
View/download PDF

48. Early Prediction of Severe Icans after CD19 CAR T-Cell Therapy Based on Serum Ferritin Levels

Author

Huang, Jennifer J, primary, Liang, Emily C., additional, Albittar, Aya, additional, Portuguese, Andrew J., additional, Wuliji, Natalie, additional, Torkelson, Aiko, additional, Kirchmeier, Delaney R., additional, Chutnik, Abigail, additional, Pender, Barbara S., additional, Shadman, Mazyar, additional, Hirayama, Alexandre V, additional, Till, Brian G, additional, Kimble, Erik L., additional, Iovino, Lorenzo, additional, Chapuis, Aude G., additional, Otegbeye, Folashade, additional, Cassaday, Ryan D., additional, Milano, Filippo, additional, Turtle, Cameron J., additional, Maloney, David G., additional, and Gauthier, Jordan, additional

Published
2024
Full Text
View/download PDF

49. Real-World Tisagenlecleucel Outcomes in Richter-Transformed Chronic Lymphocytic Leukemia: A Center for International Blood & Marrow Transplant Research (CIBMTR) Analysis

Author

Shadman, Mazyar, primary, Frigault, Matthew J., additional, Foley, Stephen Ronan, additional, Hill, Brian T., additional, Schofield, Grant, additional, Jacobson, Caron A., additional, Jaglowski, Samantha, additional, Locke, Frederick L., additional, Landsburg, Daniel J., additional, Ram, Ron, additional, Riedell, Peter A., additional, Shah, Gunjan L., additional, Popplewell, Leslie, additional, Tiwari, Ranjan, additional, Lim, Stephen, additional, Maier, Harald Jakob, additional, Majdan, Marta, additional, and Pasquini, Marcelo C., additional

Published
2024
Full Text
View/download PDF

50. Acalabrutinib in Combination with Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory B-Cell Lymphoma: A Phase I/II Study of Safety, Efficacy and Immune Correlative Analysis

Author

Poh, Christina, primary, Chow, Victor A, additional, Lynch, Ryan C, additional, Ujjani, Chaitra S, additional, Warren, Edus H, additional, Shadman, Mazyar, additional, Till, Brian G, additional, Raghunathan, Vikram, additional, Gauthier, Jordan, additional, Hirayama, Alexandre V, additional, Smith, Stephen D, additional, Gujral, Taran, additional, Morishima, Chihiro, additional, Wu, Vicky, additional, Voutsinas, Jenna M, additional, Dizon, Joshua, additional, Maloney, David G., additional, and Gopal, Ajay K, additional

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results